Resource Intervention to Support Equity (RISE) in High-Risk Neuroblastoma
NCT06831552 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 84
Last updated 2026-02-10
Summary
The goal of this study is to test if the addition of a novel income-poverty targeted supportive care intervention (Pediatric Resource Intervention to Support Equity \[Pediatric RISE\]) to usual supportive care for low-income children with high-risk neuroblastoma can improve parent- and child-centered outcomes.
Participants will be randomized to receive one of the following for 6-months:
* Usual supportive care alone or
* Usual supportive care plus Pediatric RISE
Conditions
- Neuroblastoma
- High-risk Neuroblastoma
Interventions
- BEHAVIORAL
-
RISE Intervention
Income-poverty targeted, supportive care intervention that includes direct cash transfers delivered by the Fund for Guaranteed Income, a non-profit organization, along with benefits counseling to discuss the risk of means-tested benefits loss or reduction. Funds will be dispersed to families via debit card or through personal banking, PayPal, or Venmo on a twice monthly basis for a total of twelve disbursements (6-months). Meetings with a benefits counselor will be conducted by the HIPAA-compliant video conference platform, Zoom.
Sponsors & Collaborators
- lead OTHER
Principal Investigators
-
Kira Bona, MD, MPH · Dana-Farber Cancer Institute
Study Design
- Allocation
- RANDOMIZED
- Purpose
- SUPPORTIVE_CARE
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Max Age
- 17 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-04-30
- Primary Completion
- 2029-06-01
- Completion
- 2029-06-01
Countries
- United States
Study Locations
More Related Trials
-
Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain Tumors
NCT02015728 ·Status: UNKNOWN ·Phase: NA
-
MK0752 in Treating Young Patients With Recurrent or Refractory CNS Cancer
NCT00572182 ·Status: TERMINATED ·Phase: PHASE1
-
Study of hALK.CAR T Cells for Patients With Relapsed/Refractory High-risk Neuroblastoma
NCT06803875 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, The GD2-CAR PERSIST Trial
NCT04539366 ·Status: SUSPENDED ·Phase: PHASE1
-
Therapy Based on Stage of Disease and Risk Assessment in Treating Children With Neuroblastoma
NCT00002802 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT
NCT04684368 ·Status: RECRUITING ·Phase: PHASE2
-
Study of MEK162 for Children With Low-Grade Gliomas
NCT02285439 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
High-Dose 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Myeloablative Therapy and Autologous Stem-Cell Transplantation
NCT01183416 ·Status: COMPLETED ·Phase: PHASE2
-
Genetic Study in Patients Receiving Treatment for Hodgkin's Disease or Childhood Brain Tumor
NCT00006342 ·Status: COMPLETED
-
A High Intensity Electronic Health Intervention for the Reduction of Learning Disparities in Childhood Cancer Survivors
NCT05428176 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Multiple Therapies in Treating Patients With Advanced Neuroblastoma
NCT00040872 ·Status: COMPLETED ·Phase: PHASE2
-
Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors
NCT01076530 ·Status: COMPLETED ·Phase: PHASE1
-
Gene Testing to Help in the Diagnosis and Treatment of Childhood Brain Tumors
NCT00003096 ·Status: COMPLETED
-
N2007-03: Vorinostat and 131-I MIBG in Treating Patients With Resistant or Relapsed Neuroblastoma
NCT01019850 ·Status: COMPLETED ·Phase: PHASE1
-
Local Control With Reduced-dose Radiotherapy for High-Risk Neuroblastoma
NCT02245997 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Combination Chemotherapy Followed by Stem Cell Transplant in High-risk Neuroblastoma Patients
NCT03042429 ·Status: COMPLETED ·Phase: PHASE3
-
Biological Therapy and Gene Therapy in Treating Children With Recurrent or Refractory Neuroblastoma
NCT00006480 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluation and Natural History of Children With Cancer and AIDS
NCT00001424 ·Status: COMPLETED
-
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
NCT06172296 ·Status: RECRUITING ·Phase: PHASE3
-
Temozolomide Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Malignant Glioma or Recurrent CNS or Other Solid Tumors
NCT00005952 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Safety Study of Tarceva in Children With Refractory and Relapsed Malignant Brain Tumors and Newly Diagnosed Brain Stem Glioma
NCT00418327 ·Status: COMPLETED ·Phase: PHASE1
-
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
NCT00994500 ·Status: COMPLETED ·Phase: PHASE1
-
HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors
NCT02875314 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
Chemotherapy and Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma
NCT00017225 ·Status: COMPLETED ·Phase: PHASE2
-
Gefitinib in Treating Children With Refractory Solid Tumors
NCT00040781 ·Status: COMPLETED ·Phase: PHASE1